Names Under Consideration
USAN Council's statement on the use of USAN as domain names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Illinois 60611, or sent via email to USAN@ama-assn.org.
The following list of names for the drugs described are "under consideration" by the USAN Council:
|cinhyaluronate sodium||treatment for dry eye disease|
|evinacumab||treatment of patients with severe hypertriglyceridemia, diabetic dyslipidemia, and homozygous familial hypercholesterolemia|
|flutafuranol||radioactive diagnostic agent for Alzheimer's disease|
|opicinumab||treatment of multiple sclerosis|
|sparsentan||treatment of hypertension|
|durvalumab||treatment of cancer|
|rimpetumab||treatment of cancer|
|sodium zirconium cyclosilicate||treatment of hyperkalemia|
|centanafadine||treatment of attention deficit hyperactivity disorder (ADHD)|
|linexomer||management of fluid and electrolytes in patients with heart failure and other volume overload states|
|suminersen||treatment of spinal muscular atrophy|